Cadmium Incorporated Oil Based Bioactive Polymers: Synthesis, Characterization and Physico-chemical Studies

Fabrication of metal incorporated polymer composite: An excellent antibacterial agent

US Food and Drug Administration (FDA) allowed for direct addition of castor oil for human consumption as food and most recently FDA approved castor oil as over-the-counter (OTC) for laxative drug. The present article highlights the green route phosphorylation of castor oil (COL) via condensation polymerization. Further, the incorporation of metal ions Cu (II)) and Zn (II) into the polymer matrix have been carried out at elevated temperature using catalyst p-toluene sulphonic acid (PTSA). The modification of the said material has been confirmed by FT-IR, UV-VIS, and ¹H and ³¹P-NMR spectroscopy. Further, the in vitro antibacterial activities of the metal incorporated-COL has been performed by standard methods against B. cereus (MCC2243) (gram-positive) and E. coli (MCC2412) (gram-negative) bacteria. The results revealed that the incorporation of metal ions into the polymer matrix increases the antibacterial activity largely. This may be governed by the electrostatic interaction between metal ions and microbes, also the generation of free active oxygen hinders the normal activity of bacteria. These results suggest that the synthesized material may act a potential candidate for low cost, environment friendly antibacterial agents and may find their application in clinical fields. Herein we are also proposing mechanism of antibacterial activity.

Green Ultrasound versus Conventional Synthesis and Characterization of Specific Task Pyridinium Ionic Liquid Hydrazones Tethering Fluorinated Counter Anions: Novel Inhibitors of Fungal Ergosterol Biosynthesis

A series of specific task ionic liquids (ILs) based on a pyridiniumhydrazone scaffold in combination with hexafluorophosphate (PF₆-), tetrafluoroboron (BF₄-) and/or trifluoroacetate (CF₃COO-) counter anion, were designed and characterized by IR, NMR and mass spectrometry. The reactions were conducted under both conventional and green ultrasound procedures. The antifungal potential of the synthesized compounds 2-25 was investigated against 40 strains of Candida (four standard and 36 clinical isolates). Minimum inhibitory concentrations (MIC90) of the synthesized compounds were in the range of 62.5-2000 μg/mL for both standard and oral Candida isolates. MIC90 results showed that the synthesized 1-(2-(4-chlorophenyl)-2-oxoethyl)-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)-pyridin-1-ium hexafluorophosphate (11) was found to be most effective, followed by 4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)-1-(2-(4-nitrophenyl)-2-oxoethyl)-pyridin-1-ium hexafluorophosphate (14) and 1-(2-ethoxy-2-oxoethyl)-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridin-1-ium hexafluorophosphate (8). All the Candida isolates showed marked sensitivity towards the synthesized compounds. Ergosterol content was drastically reduced by more active synthesized compounds, and agreed well with MIC90 values. Confocal scanning laser microscopy (CLSM) results showed that the red colored fluorescent dye enters the test agent treated cells, which confirms cell wall and cell membrane damage. The microscopy results obtained suggested membrane-located targets for the action of these synthesized compounds. It appears that the test compounds might be interacting with ergosterol in the fungal cell membranes, decreasing the membrane ergosterol content and ultimately leading to membrane disruption as visible in confocal results. The present study indicates that these synthesized compounds show significant antifungal activity against Candida which forms the basis to carry out further in vivo experiments before their clinical use.